Evaluating LDL-C Recommendations

2013 ACC/AHA Cholesterol Guidelines Four Statin Benefit Groups Identified

IMPROVE-IT Simvastatin 40 mg vs Simvastatin/Ezetimibe 40 mg/10 mg

IMPROVE-IT (cont)

IMPROVE-IT (cont)

IMPROVE-IT vs CTT Ezetimibe vs Statin Benefit

JUPITER and TNT Trials Evidence That Lower LDL-C Is Better

ODYSSEY LONG-TERM Alirocumab 150 mg vs Placebo 2:1

ODYSSEY LONG-TERM (cont)

OSLER Evolocumab + Standard Therapy vs Standard Therapy Alone 2:1

ODYSSEY LONG-TERM AEs by Achieved LDL-C

GAUSS-2 and ODYSSEY ALTERNATIVE PCSK9 Inhibitors Well Tolerated by Statin-intolerant Patients

PROVE-IT TIMI 22 Intensive vs Moderate Statin Therapy After ACS

Meta-analysis of Statin Trials Risk of Major CV Events by LDL-C Level

Ongoing PCSK9 Inhibitor CVD Outcomes Trials

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)